News

Bioequivalence Study of Sublingual BHV-0223 Shows Positive Results as Rilutek Substitute

A dissolving tablet version of riluzole called BHV-0223 has shown positive bioequivalence when compared to the oral form of the therapy, Rilutek, developer Biohaven Pharmaceuticals announced. The dissolving tablet, placed under the tongue, is easier to administrate to patients with amyotrophic lateral sclerosis (ALS) who have trouble swallowing. BHV-0223 also was found…

Canada’s NeuroSGC Partnership Seeks Potential Treatments for ALS, Parkinson’s Disease

NeuroSGC, a new scientific partnership formed by the Structural Genomics Consortium (SGC) and the Montreal Neurological Institute and Hospital (The Neuro) aims to discover new treatments for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease — both of which currently lack effective therapies. Drug discovery for these and other neurological…

American CryoStem’s Atcell Not Approved for ALS, Other Neurodegenerative Diseases, FDA Warns

The U.S. Food and Drug Administration (FDA) has issued a warning to the American CryoStem Corporation of Monmouth Junction, New Jersey, for marketing Atcell, the company’s adipose-derived stem cell product, without FDA approval. In its warning letter, the FDA noted “significant deviations from current good manufacturing practice requirements, including some…

Cell Stress Unleashes Downward Spiral of Toxic Protein Production in ALS

Cell stress, such as a viral infection, may trigger the production of faulty proteins from the C9orf72 gene, a leading contributor of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), say researchers at the University of Michigan. Their study, “RAN translation at C9orf72-associated repeat expansions is selectively enhanced…